文献速递消化系统肿瘤

基于数字病理的预测胃肠道肿瘤预后及辅助治疗获益的基础模型

Foundation Model for Predicting Prognosis and Adjuvant Therapy Benefit From Digital Pathology in GI Cancers.
PubMed 文献 · J Clin Oncol · 2025-04-01

该跨国队列研究基于自监督学习训练病理基础模型,并在七个队列中验证其对胃癌、食管癌和结直肠癌生存的预测能力;模型可分层高低风险,且辅助化疗仅在高风险II/III期胃癌和结直肠癌中与生存改善相关。

要点

  • AI模型预测胃癌无病生存和疾病特异性生存的C指数为0.726-0.797,结直肠癌为0.714-0.757。
  • 模型划分高风险与低风险组,胃癌5年生存率49%-52%对76%-92%,结直肠癌43%-72%对81%-98%。
  • II/III期胃癌和结直肠癌中,辅助化疗仅在高风险组与生存改善相关(交互P=.01和.006)。

核心结论

  • 病理基础模型能准确预测胃肠道肿瘤生存结局并补充临床病理因素。
  • 在有待前瞻性验证的前提下,该模型可能用于改善风险分层并为个性化辅助治疗提供信息。

研究设计与样本

  • 跨国队列研究,基于苏木精-伊红染色组织病理切片开发AI模型预测胃肠道肿瘤预后。
  • 在七个队列中验证模型预测生存结局,包括1619例胃癌和食管癌患者及2594例结直肠癌患者。
  • 进一步评估模型预测辅助化疗生存获益的能力。

主要发现

  • 验证队列中AI模型预测胃癌无病生存和疾病特异性生存的C指数为0.726-0.797,结直肠癌为0.714-0.757。
  • 模型将患者分为高风险和低风险组,胃癌5年生存率49%-52%对76%-92%,结直肠癌43%-72%对81%-98%。
  • 多变量分析中,校正临床病理变量后AI风险评分仍为独立预后因素。
  • 与仅用分期相比,分期加图像信息的整合模型在所有验证队列中均改善预后预测。
  • II/III期胃癌和结直肠癌中,辅助化疗在高风险组与生存改善相关,低风险组无此关联(治疗-模型交互P=.01和.006)。

关键数值与推荐

  • 胃癌验证队列C指数0.726-0.797,结直肠癌验证队列C指数0.714-0.757。
  • 高风险组对低风险组5年生存率:胃癌49%-52%对76%-92%,结直肠癌43%-72%对81%-98%。
  • II/III期胃癌和结直肠癌辅助化疗治疗-模型交互P=.01和.006。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出该模型尚待前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Artificial intelligence (AI) holds significant promise for improving cancer diagnosis and treatment. Here, we present a foundation AI model for prognosis prediction on the basis of standard hematoxylin and eosin-stained histopathology slides. METHODS: In this multinational cohort study, we developed AI models to predict prognosis from histopathology images of patients with GI cancers. First, we trained a foundation model using over 130 million patches from 104,876 whole-slide images on the basis of self-supervised learning. Second, we fine-tuned deep learning models for predicting survival outcomes and validated them across seven cohorts, including 1,619 patients with gastric and esophageal cancers and 2,594 patients with colorectal cancer. We further assessed the model for predicting survival benefit from adjuvant chemotherapy. RESULTS: The AI models predicted disease-free survival and disease-specific survival with a concordance index of 0.726-0.797 for gastric cancer and 0.714-0.757 for colorectal cancer in the validation cohorts. The models stratified patients into high-risk and low-risk groups, with 5-year survival rates of 49%-52% versus 76%-92% in gastric cancer and 43%-72% versus 81%-98% in colorectal cancer. In multivariable analysis, the AI risk scores remained an independent prognostic factor after adjusting for clinicopathologic variables. Compared with stage alone, an integrated model consisting of stage and image information improved prognosis prediction across all validation cohorts. Finally, adjuvant chemotherapy was associated with improved survival in the high-risk group but not in the low-risk group (treatment-model interaction P = .01 and .006) for stage II/III gastric and colorectal cancer, respectively. CONCLUSION: The pathology foundation model can accurately predict survival outcomes and complement clinicopathologic factors in GI cancers. Pending prospective validation, it may be used to improve risk stratification and inform personalized adjuvant therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wang X, Jiang Y, Yang S, et al. Foundation Model for Predicting Prognosis and Adjuvant Therapy Benefit From Digital Pathology in GI Cancers. J Clin Oncol. 2025. PMID: 40168636. doi:10.1200/JCO-24-01501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。